SCHISTOSOMIASIS
PEDIATRIC PRAZIQUANTEL CONSORTIUM
Treating preschool children

THE IMPACT OF SCHISTOSOMIASIS

- More than 700 million people at risk
- At least 220 million people require treatment
- Nearly half are school-age children
- 120 million people with morbidity
- Many disabling complications
- High infection rates in young children
- No suitable treatment for preschool-age children

Merck KGaA (Darmstadt, Germany) leads the program. Expert in praziquantel, it provides resources and support from different areas: pre-clinical, clinical, drug substance/drug product development and manufacturing, regulatory and access. It is responsible for the clinical development program and is the sponsor of the clinical trials.

Astellas Pharma Inc. (Japan) has developed the new pediatric PZQ formulations, and provides expert advice on clinical development in children, and pharmacokinetic modeling.

The Swiss Tropical and Public Health Institute (Switzerland) is a world-leading institute in global health with a particular focus on low- and middle-income countries. Associated with the University of Basel, Swiss TPH combines research, services, and education and training at local, national and international levels. About 850 people from 80 nations work at Swiss TPH focusing on infectious and non-communicable diseases, environment, society and health as well as health systems and interventions.

Lygature (The Netherlands), a not-for-profit foundation, acts as the independent coordinator of the Consortium, providing governance in terms of progress, finance and collaboration. Since 2006, Lygature has supported close to a hundred public-private partnerships in the field of life sciences & health, including poverty-related diseases.

Farmanguinhos (Brazil), the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to addressing the production and distribution of new pediatric formulations in endemic countries.

The SCI Foundation (United Kingdom), is a non-profit initiative that supports treatment programs against schistosomiasis and soil-transmitted helminthiasis in sub-Saharan African countries and Yemen. It will facilitate preparation and implementation of the Access and Delivery plan.

Kenya Medical Research Institute (Kenya) provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the conduct of the trials in Kenya according to Good Clinical Practice and national and local regulatory and ethics standards.

Université Félix Houphouët-Boigny (Côte d’Ivoire) was previously involved in the phase II clinical trials of the pediatric praziquantel formulation. It provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the phase III trials in Côte d’Ivoire according to Good Clinical Practice and national and local regulatory and ethics standards.
Schistosomiasis is one of the most prevalent parasitic diseases in Africa, and a very important one in terms of public health burden and economic impact. Left untreated, this poverty-related disease can lead to anemia, stunted growth and impaired learning ability, as well as chronic inflammation of the organs, which can be fatal in the most serious cases.
As efforts focus on morbidity control and elimination, there is a pressing need to treat preschool-age children (under 6 years old). No suitable drug formulation is available for this high-risk group, which accounts for an estimated 50 million of the 220 million people already infected³.

THE STANDARD OF CARE TREATMENT

The existing ‘standard of care’ treatment for schistosomiasis is praziquantel (PZQ), which was developed in the 1970s. This oral anthelmintic is available as generic drug and currently donated through the Praziquantel Donation Program of Merck KGaA, Darmstadt, Germany, via the World Health Organization (WHO), mainly to school-age children, to fight schistosomiasis in Africa. It is safe and effective, and a tablet formulation is available for adults and school-age children but not for those below 6 years old.

The existing PZQ formulation is a racemic mixture of levopraziquantel (L-PZQ) and dextropraziquantel (D-PZQ). Only one of these components is pharmacologically active: the L-PZQ enantiomer. The other component, D-PZQ has been shown to be inactive and significantly contributes to the taste that makes treating young children difficult.

THE NEW PZQ FORMULATION

The Pediatric Praziquantel Consortium has developed a pediatric formulation that is more suitable for younger children, including infants and toddlers. The formulation is smaller, orodispersible and has improved taste properties compared to the currently available 600 mg tablet.

Two novel PZQ formulation candidates have been developed and tested by the Consortium: a racemic mixture (rac-PZQ) and an enantiopure version (L-PZQ). The clinical phase II trial testing both formulations in children (aged 2 to 6 years) confirmed the formulation with L-PZQ as the one to be pursued by the Consortium until registration. The Consortium program is in clinical Phase III to acquire confirmatory data needed by the regulators.

Schistosomiasis is one of the most prevalent parasitic diseases in Africa, and a very important one in terms of public health burden and economic impact. Left untreated, this poverty-related disease can lead to anemia, stunted growth and impaired learning ability, as well as chronic inflammation of the organs, which can be fatal in the most serious cases.

As efforts focus on morbidity control and elimination, there is a pressing need to treat preschool-age children (under 6 years old). No suitable drug formulation is available for this high-risk group, which accounts for an estimated 50 million of the 220 million people already infected.

The existing 'standard of care' treatment for schistosomiasis is praziquantel (PZQ), which was developed in the 1970s. This oral anthelmintic is available as generic drug and currently donated through the Praziquantel Donation Program of Merck KGaA, Darmstadt, Germany, via the World Health Organization (WHO), mainly to school-age children, to fight schistosomiasis in Africa. It is safe and effective, and a tablet formulation is available for adults and school-age children but not for those below 6 years old.

The existing PZQ formulation is a racemic mixture of levopraziquantel (L-PZQ) and dextropraziquantel (D-PZQ). Only one of these components is pharmacologically active: the L-PZQ enantiomer. The other component, D-PZQ has been shown to be inactive and significantly contributes to the taste that makes treating young children difficult.

The Pediatric Praziquantel Consortium has developed a pediatric formulation that is more suitable for younger children, including infants and toddlers. The formulation is smaller, orodispersible and has improved taste properties compared to the currently available 600mg tablet. Two novel PZQ formulation candidates have been developed and tested by the Consortium: a racemic mixture (rac-PZQ) and an enantiopure version (L-PZQ). The clinical phase II trial testing both formulations in children (aged 2 to 6 years) confirmed the formulation with L-PZQ as the one to be pursued by the Consortium until registration. The Consortium program is in clinical Phase III to acquire confirmatory data needed by the regulators.

The Consortium is financially supported by Merck KGaA, Darmstadt, Germany, in-kind contributions by partners and by grants from the Bill & Melinda Gates Foundation (2013), from the Global Health Innovative Technology Fund (2014, 2015, 2016 and 2019), and the European & Developing Countries Clinical Trials Partnership (2018).
THE IMPACT OF SCHISTOSOMIASIS

- More than 700 million people at risk
- At least 220 million people require treatment
- Nearly half are school-age children
- 120 million people with morbidity
- Many disabling complications
- High infection rates in young children
- No suitable treatment for preschool-age children

Merck KGaA (Darmstadt, Germany) leads the program. Expert in praziquantel, it provides resources and support from different areas: pre-clinical, clinical, drug substance/drug product development and manufacturing, regulatory and access. It is responsible for the clinical development program and is the sponsor of the clinical trials.

Astellas Pharma Inc. (Japan) has developed the new pediatric PZQ formulations, and provides expert advice on clinical development in children, and pharmacokinetic modeling.

The Swiss Tropical and Public Health Institute (Switzerland) is a world-leading institute in global health with a particular focus on low- and middle-income countries. Associated with the University of Basel, Swiss TPH combines research, services, and education and training at local, national and international levels. About 850 people from 80 nations work at Swiss TPH focusing on infectious and non-communicable diseases, environment, society and health as well as health systems and interventions.

Lygature (The Netherlands), a not-for-profit foundation, acts as the independent coordinator of the Consortium, providing governance in terms of progress, finance and collaboration. Since 2006, Lygature has supported close to a hundred public-private partnerships in the field of life sciences & health, including poverty-related diseases.

Farmanguinhos (Brazil), the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to addressing the production and distribution of new pediatric formulations in endemic countries.

The SCI Foundation (United Kingdom), is a non-profit initiative that supports treatment programs against schistosomiasis and soil-transmitted helminthiasis in sub-Saharan African countries and Yemen. It will facilitate preparation and implementation of the Access and Delivery plan.

Kenya Medical Research Institute (Kenya) provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the conduct of the trials in Kenya according to Good Clinical Practice and national and local regulatory and ethics standards.

Université Félix Houphouët-Boigny (Côte d’Ivoire) was previously involved in the phase II clinical trials of the pediatric praziquantel formulation. It provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the phase III trials in Côte d’Ivoire according to Good Clinical Practice and national and local regulatory and ethics standards.

www.pediatricpraziquantelconsortium.org